

REVIEW ARTICLE

Kawasaki Disease: An Update on Diagnosis and Treatment

Ho-Chang Kuo ^{a,b}, Kuender D. Yang ^c, Wei-Chiao Chang ^d, Luo-Ping Ger ^e, Kai-Sheng Hsieh ^{f,g,*}

^a Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Taiwan

^b Chang Gung University College of Medicine, Kaohsiung, Taiwan

^c Department of Medical Research, Show Chwan Memorial Hospital in Chang Bing, Changhua, Taiwan

^d Department of Medical Genetics, Kaohsiung Medical University, Taiwan

^e Department of Medical Education, Kaohsiung Veterans General Hospital, Taiwan

^f Department of Pediatrics, Kaohsiung Veterans General Hospital, Taiwan

^g National Yang-Ming University, Taiwan

Received Apr 19, 2011; received in revised form Sep 13, 2011; accepted Sep 27, 2011

Key Words

coronary artery lesion;
IVIG;
Kawasaki disease

Kawasaki disease (KD) is an acute multi-system vasculitis syndrome of unknown etiology occurring mostly in infants and children younger than 5 years of age. In developed countries, it is the leading cause of acquired heart disease in children. However, KD remains a mysterious disease. Some viruses potentially causing the condition have been isolated, but the results have not been able to be reproduced. This article reviews and summarizes different aspects of KD and provides updated information on diagnosis and treatment. The supplementary criteria for incomplete presentation of KD patients suggested by the American Heart Association, treatment (including tumor necrosis factor- α antagonist, methylprednisolone pulse therapy, statins, plasma exchange, and cytotoxic agents) for those with intravenous immunoglobulin treatment failure, and other experiences are also included in this review.

Copyright © 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.

1. Introduction

Kawasaki disease (KD) is an acute febrile systemic vasculitis that was first described by Kawasaki et al¹ in 1974. In developed countries, it is the leading cause of acquired heart disease in children, however its etiology remains

* Corresponding author. Department of Pediatrics, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung 813, Taiwan.

E-mail address: kshsieh@isca.vghks.gov.tw (K.-S. Hsieh).

unknown.^{2–4} KD mainly affects children less than 5 years of age, especially those in Asian countries, but its incidence has increased worldwide. In Japan, Korea, and Taiwan, the incidence ranges from 69 to 218 cases per 100,000 children less than 5 years of age.^{5–7} The incidence of KD in Taiwan has increased from 66 to 69 per 100,000 children aged less than 5 years.^{5–8} An epidemiologic survey of KD in Taiwan from 2003 to 2006 found that 1.5% of all cases were recurrent.⁶ In Taiwan, KD occurs most frequently in the summer (April to June) and least frequently in the winter, but for unknown reasons, its seasonal occurrence varies in other countries. The most serious complication of KD is the involvement of coronary artery lesions (CAL), including myocardial infarction, coronary artery fistula formation,⁹ coronary artery dilatation, and coronary artery aneurysm.¹⁰

The most commonly used definition of CAL (also known as coronary artery abnormality, CAA, or CALs) is based on the Japanese Ministry of Health criteria: maximum absolute internal diameter >3 mm in children younger than 5 years of age or >4 mm in children 5 years and older, or a segmental diameter 1.5 times greater than that of an adjacent segment, or the presence of luminal irregularity.^{11–15} Coronary arteries should be corrected relative to body surface area (if available) and expressed as standard deviation units from the mean (Z scores).¹⁶ Several studies have analyzed CAL, including aortic root dimension,¹⁷ and transient CAL (the definition of “transient” varies among studies, from 30 days to 6–8 weeks after diagnosis of disease). As such, KD patients with coronary artery ectasia or dilatation, which disappears within the first 8 weeks after disease onset, are defined as transient ectasia or dilatation (transient CAL). According to our previous report on CAL analysis including 341 KD patients,¹⁸ 35% of KD patients had dilatation during the acute phase of admission, 17.2% had dilatation 1 month after disease onset, 10.2% had dilatation at 2 months, and 4% had persistent CAL for more than 1 year.¹⁹

Although the clinical features of KD are recognizable, its underlying immunopathogenetic mechanisms are still under investigation, particularly the agent responsible for the development of CAL. KD is regarded as an autoimmune disorder rather than an infectious disease.¹⁷ Kuo et al²⁰ reported that persistent monocytosis after intravenous immunoglobulin (IVIG) treatment is associated with CAL formation. Eosinophils were also higher in KD patients than in age-matched febrile controls. In addition, IVIG treatment significantly increased eosinophils in KD patients. This increase of eosinophils after IVIG treatment is inversely correlated with IVIG treatment failure in KD.²¹ Further studies have shown that changes of eosinophils after IVIG treatment were positively correlated with changes in interleukin (IL)-5 levels. An increase in eosinophils and IL-5 levels after IVIG treatment was inversely correlated with CAL formation.²²

Immune- and apoptosis-related genes [cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), caspase 3 (CASP3), IL-10, IL-1B, CD40L, programmed death 1 (PD-1), ORAI1, and inositol 1,4,5-trisphosphate 3-kinase C (ITPKC)] have been associated with susceptibility and/or disease outcome,^{13,15,18,19,22–30} further highlighting the involvement of immune responses and imbalances between T helper cell 1/2 (Th1/Th2) immune responses in the

pathogenesis of KD. A skewed Th2 response (eosinophil and IL-5 levels) may indicate good IVIG treatment response and subsequent disease outcome. Weng et al²⁶ reported that an IL-10 gene polymorphism is associated with CAL formation and IL-1B is associated with IVIG treatment response.²⁵ Some studies of genetic variants also found a difference between male and female genders, including CTLA-4 and cytokine genes (IL-1B, IL-4, IL-8, and IL-10).^{30,31} Shimizu et al¹⁷ reported that the transforming growth factor-beta (TGF- β) signaling pathway influences KD susceptibility, disease outcome, and the response to IVIG therapy, and also shows immune response dysregulation. The inheritance patterns of these traits have not been described in these studies. It is likely that multiple polymorphic alleles influence KD susceptibility and disease outcome. This suggests that different ethnic populations and different genders may have different susceptibilities to KD.

The diagnosis and treatment of KD has become one of the most controversial issues for pediatricians in Taiwan, based on a nationwide questionnaire conducted by the Taiwan Pediatric Association in 2009. This article reviews updated information on KD and focuses on diagnosis and treatment aspects of the disease.

2. Updates on the Diagnosis of Kawasaki Disease

The clinical characteristics of KD patients include prolonged fever lasting longer than 5 days, diffuse mucosal inflammation, bilateral nonpurulent conjunctivitis, dysmorphic skin rashes, indurative angioedema over the hands and feet, and cervical lymphadenopathy. In addition to the diagnostic criteria, there is a broad range of nonspecific clinical features, including irritability, uveitis, aseptic meningitis, cough, vomiting, diarrhea, abdominal pain, gallbladder hydrops, urethritis, arthralgia, arthritis, hypoalbuminemia,⁴ liver function impairment, and heart failure.^{3,21,32}

To date, there is no specific diagnostic test for KD. Diagnosis is based on the presence of fever lasting longer than 5 days and four of five specific clinical criteria. In Japan, at least five of six criteria (fever and five other clinical criteria) should be fulfilled for a diagnosis of KD. However, patients with four of the principal clinical features can be diagnosed when coronary aneurysm or dilatation is recognized.²⁴ From the Japanese Circulation Society Joint Working Groups criteria (JCS 2008, Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease),³³ KD can be diagnosed even when fever lasts less than 5 days. However, according to the American Heart Association (AHA) criteria,¹⁰ fever lasting more than 5 days is essential for KD diagnosis (comparison of diagnosis criteria from JCS and AHA is shown in Table 1).

Some patients who do not fulfill the criteria outlined in Table 1 have been diagnosed with “incomplete” or “atypical” KD, a diagnosis often based on echocardiographic identification of CAL. The term “incomplete” may be preferable to “atypical” because these patients have insufficient criteria instead of atypical presentation.¹⁰

In countries with a bacillus Calmette-Guérin (BCG) vaccine policy (i.e., Taiwan and Japan), KD with erythematous induration or even ulceration of the BCG scars has

Table 1 Comparison of the diagnostic criteria of Kawasaki disease.

AHA criteria 2004	JCS 2008 Guidelines
Fever ≥ 5 days and at least 4 of the following 5	At least 5 of the following 6
Bilateral nonsuppurative conjunctivitis	The same
One or more changes to the mucous membranes including pharyngeal injection, dry fissured lips, injected lips, and strawberry tongue	The same
Indurative angioedema of the hands and feet including peripheral erythema, peripheral edema, periungual desquamation, and generalized desquamation	The same
Dysmorphic skin rashes	The same
Acute nonpurulent cervical lymphadenopathy >1.5 cm in diameter	The same
	Fever*

*Fever of more than 5 days is essential for diagnosis in AHA (American Heart Association) 2004 criteria but not in the JCS (Japanese Circulation Society) 2008 criteria.

been observed in one-third to half of KD patients (the incidence of BCG site induration is higher than that of neck lymphadenopathy in these countries).² Uehara et al³⁴ reported that redness or the formation of a crust at the BCG inoculation site is a useful diagnostic sign for KD in children aged 3–20 months. Even if patients have four or fewer signs of the clinical criteria for KD, physicians should consider the redness or crust formation at the BCG inoculation site as a possible indicator of KD.

Atypical cases of KD are not uncommon (up to 15–20%). The incidence of CAL in patients exhibiting four principal symptoms of KD is slightly higher than in patients with five to six principal symptoms.³⁵ Presentation of a small number (< 4) of principal symptoms does not indicate a milder form of the disease. Patients with at least four principal symptoms require the same treatment as patients with complete (typical) KD, and those with three or fewer principal symptoms should be treated similarly when they meet the supplementary criteria. Herein, common supplementary criteria for the diagnosis of incomplete KD are introduced.

3. American Heart Association (AHA) Criteria 2004

Incomplete KD is more common in young infants than in older children, making accurate diagnosis and timely treatment especially important in these young patients who are at substantial risk of developing coronary abnormalities.^{36,37} The incidence of KD is actually higher than previously reported throughout the world, partly because earlier reports did not take incomplete forms into account. The AHA criteria (2004), which incorporate suggestions for laboratory tests and early echocardiography, are helpful for diagnosing incomplete KD.^{32,38} Consultation with an expert (cardiologist, immunologist, or rheumatologist) should be sought at any time when assistance in making a diagnosis is needed. Patients with fever for \geq five days (with 2 or 3 principal clinical features for KD) without other explanation should undergo laboratory testing, and if there is evidence of systemic inflammation, an echocardiogram should be obtained even if the patient does not fully meet the clinical criteria for KD. Infants ≤ 6 months old with fever for ≥ 7 days without other explanation should undergo laboratory testing, and if evidence of systemic inflammation is found,

an echocardiogram should be obtained even if the infant has no clinical criteria for KD.¹⁰

The 2004 AHA supplemental laboratory criteria (Table 2) include: (1) albumin ≤ 3.0 g/dL; (2) anemia for age; (3) elevation of alanine aminotransferase; (4) platelets after 7 days $\geq 450,000/\text{mm}^3$; (5) white blood cell count $\geq 15,000/\text{mm}^3$; and (6) urine ≥ 10 white blood cells/high-power field.¹⁰ If a patient has more than three supplementary criteria, incomplete KD is diagnosed and IVIG should be prescribed before performing echocardiography.¹⁰

4. Updates on the Treatment of Kawasaki Disease

4.1. Aspirin

Aspirin has been used in the treatment of KD for many years, even before the advent of IVIG. Although aspirin has important anti-inflammatory (high-dose) and antiplatelet (low-dose) activity, it does not appear to lower the frequency of CAL formation. During the acute phase of the illness, aspirin is administered at 80 to 100 mg/kg per day (30–50 mg/kg in Japan)³⁹ in four doses with IVIG. High-dose aspirin and IVIG appear to possess additive anti-inflammatory effects.

Table 2 Supplementary laboratory criteria for incomplete Kawasaki disease.

Fever of >5 d associated with 2 or 3 clinical criteria, C-reactive protein ≥ 3.0 mg/dL and/or erythrocyte sedimentation rate ≥ 40 mm/h with the following criteria
(1) albumin ≤ 3.0 g/dL
(2) anemia for age
(3) elevation of alanine aminotransferase
(4) platelets after 7 d $\geq 450,000/\text{mm}^3$
(5) white blood cell count $\geq 15,000/\text{mm}^3$
(6) urine ≥ 10 white blood cells/high-power field

Modified from Newburger et al.¹⁰

If ≥ 3 supplement criteria are met, intravenous immunoglobulin can be prescribed before performing echocardiography. CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; IVIG = intravenous immunoglobulin.

Practices regarding the duration of high-dose aspirin administration vary across countries and centers, many of which reduce the aspirin dose when the patient is afebrile. When high-dose aspirin is discontinued, low-dose aspirin (3–5 mg/kg/day) is given until there is no evidence of CAL and inflammatory markers [including platelets, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR)] have returned to normal levels, which usually occurs 6–8 weeks after disease onset. For children who develop CAL, low-dose aspirin (or other antiplatelet agents) is continued indefinitely until the inflammatory markers return to the normal range and the echocardiogram does not show abnormalities. Hsieh et al³⁹ reported that regardless of timing (before or after Day 5 of the illness), single-infusion, high-dose (2 g/kg) aspirin in the acute stage of KD had no effect on the response rate to IVIG therapy, duration of fever, or the incidence of CAL. This review reiterates the recommendation that exposing children to high-dose aspirin therapy in the acute phase of KD is unnecessary because available data show no appreciable benefit to IVIG therapy response, CAL formation, or fever duration.

Our recent study investigated 609 KD patients from two medical centers in Taiwan.⁴⁰ The patients were divided into Group 1, with high-dose aspirin ($n = 274$), and Group 2, without high-dose aspirin ($n = 335$). There were no significant differences between groups 1 and 2 in terms of gender ($p = 0.51$), IVIG resistance rate (34/274 vs. 26/335, $p = 0.06$), CAL formation rate (57/274 vs. 74/335, $p = 0.64$), and total hospital stay (6.3 ± 0.2 vs. 6.7 ± 0.2 , $p = 0.13$). There were also no significant differences between total white blood counts, hemoglobin levels, platelet counts, and CRP levels before (within 1 day) and after (within 3 days) IVIG treatment between the two groups ($p > 0.1$). These results provide evidence that high-dose aspirin in the acute phase of KD does not affect the treatment results (CAL and IVIG resistance rate) or inflammatory condition. High-dose aspirin treatment in the acute phase of KD seems to be unnecessary and further randomized controlled trials are needed.

4.2. Intravenous immunoglobulin (IVIG) responsiveness

The efficacy of IVIG administered in the acute phase of KD for reducing the incidence of coronary artery abnormalities is well established.⁴¹ The mechanism of IVIG action is still under investigation. IVIG appears to have a generalized anti-inflammatory effect. Possible mechanisms of action include modulation of cytokine production, neutralization of bacterial super-antigens or other etiologic agents, augmentation of regulatory T cell activity (TGF- β),¹⁷ suppression of antibody synthesis and inflammatory markers (CD40L, nitric oxide, and iNOS expression),^{42,43} providing of anti-idiotypic antibodies, and balancing Th1/Th2 responses.^{20–22}

KD patients should be treated with a single 12-hour infusion of IVIG, 2 g/kg in a single infusion, together with aspirin in acute phase with fever, or inflammation progression without fever.^{2,3,10} This therapy should be performed within 10 days of illness onset, and if this is not possible, within 7 days of illness onset. Treatment of KD

before Day 5 of the illness appears no more likely to prevent cardiac sequelae than treatment on Days 5–9. It may, however, be associated with an increased need for IVIG retreatment.^{44,45} In the presence of four of five classic criteria for KD, US and Japanese experts agree that only 4 days of fever are necessary before initiating treatment with IVIG.^{10,46}

The efficacy of treating patients using IVIG after 10 days of illness is unknown; therefore, early diagnosis and treatment is desired. IVIG should be administered to children presenting after Day 10 of illness (i.e., children with delayed diagnosis or incomplete KD) if they have either persistent fever without explanation or aneurysms and ongoing systemic inflammation, as manifested by elevated ESR or CRP.^{3,47–49} Burns et al³ also suggested that any child with KD who has evidence of persisting inflammation, including fever or high concentrations of inflammatory markers with or without coronary artery abnormalities, should be treated even if the diagnosis is made after 10 days of illness.

4.3. IVIG resistance (initial IVIG treatment failure)

The incidence of IVIG resistance varies between centers, from 9.4% to 23% (but it can be as high as 38%, as reported in one American cohort).⁵⁰ Recent studies have identified demographic and laboratory characteristics as predictors of IVIG resistance, including age, illness day, platelet count, ESR, hemoglobin concentration, CRP, eosinophil, lactate dehydrogenase, albumin, and alanine aminotransferase (ALT).^{4,21,51–53} Because IVIG-resistant patients are at a higher risk for CAL formation, it is important to identify those who may benefit from a more aggressive therapy. As shown in Figure 1 (modified from Newburger et al¹⁰), there are no definite treatment principles available for the management of KD patients with initial IVIG resistance or unresponsiveness to other adjuvant therapies. A second dose of IVIG (1 g/kg or 2 g/kg),^{10,54} methylprednisolone pulse therapy,⁵⁵ tumor necrosis factor-alpha (TNF- α) blockade,⁵⁶ cytotoxic agents (cyclophosphamide, cyclosporine A, or MTX⁵⁷), plasmapheresis,⁵⁸ and plasma exchange⁵⁹ have been reported to benefit KD patients with initial IVIG treatment failure. These other treatment modalities will be discussed.

4.4. Methylprednisolone (MP) pulse therapy

At present, the usefulness of steroids in the initial treatment of KD is not well established.¹⁰ Newburger et al¹⁶ reported that single-pulsed dose of intravenous methylprednisolone (IVMP) compared to conventional IVIG therapy for routine primary treatment of KD in children does not improve treatment outcome. However, IVMP therapy seems to benefit IVIG-resistant KD patients.⁶⁰ Miura et al⁶¹ revealed the effectiveness of IVMP therapy for KD patients that were previously unresponsive to initial IVIG treatment. IVMP suppresses cytokine levels faster, and subsequently, the outcomes are similar to those of IVIG responsive patients who receive a second dose of IVIG. Furukawa et al⁶² reported similar findings. IVMP seems to have the same effect on IVIG-resistant KD patients




Figure 1 Flow chart reference for the management of refractory and incomplete Kawasaki disease (KD) (modified from Newburger et al¹⁰). *There were no definite treatment principles available for the management of KD patient with initial IVIG resistance or unresponsiveness to other adjuvant therapies. Second dose of IVIG (1 g/kg or 2 g/kg),^{10,54} methylprednisolone pulse therapy,⁵⁵ tumor necrosis factor- α blockade,⁵⁶ cytotoxic agents (cyclophosphamide, cyclosporine A, or MTX⁵⁷), plasmapheresis,⁵⁸ and plasma exchange⁵⁹ have been reported to benefit KD patient with initial IVIG treatment failure. Supplemental laboratory criteria for incomplete KD were as shown in Table 2. AHA = American Heart Association; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; KD = Kawasaki disease; IVIG = intravenous immunoglobulin; 2D echo = two-dimensional echocardiography; TNF- α = tumor necrosis factor- α .

compared to an additional IVIG treatment.³³ The cost-benefit differences between IVMP and additional IVIG should be carefully considered, taking into account different medical conditions or health insurance policies among countries. The first dose of IVIG is well established, while IVMP or additional IVIG for IVIG-resistant KD patients requires further investigation. Ogata et al³³ reported that IVMP was useful to reduce fever duration and medical costs for KD patients with initial IVIG resistance. IVMP ($n = 13$) and additional IVIG treatment ($n = 14$) were not significantly different in terms of preventing the development of coronary artery aneurysm. IVMP (methylprednisolone

30 mg/kg per day for 3 days) or a second dose of IVIG (2 g/kg) was prescribed to KD patients with fever and marked inflammation (i.e., nonexudative conjunctival injection, strawberry tongue, fissure lips, and erythematous change at the BCG inoculation site) 48 hours after initial IVIG treatment.^{16,33,62,63}

The safety of IVMP therapy in patients with KD is uncertain. Miura et al⁶⁴ reported that IVMP ($n = 11$) incurred a higher incidence of sinus bradycardia and hyperglycemia when compared with the additional IVIG group ($n = 11$). Hypertension did not differ significantly between IVMP and IVIG groups. All of the adverse effects were transient. There were no convulsions, gastrointestinal symptoms, infections, malignant arrhythmias, or sudden deaths in any subjects.⁶⁴ Taken together, IVMP is safe for KD patients as additional or adjuvant therapy of initial IVIG treatment.^{16,65,66} After additional IVIG therapy, IVMP is considered for KD patients with persistently poor responses to the second IVIG treatment.^{54,67}

4.5. Tumor necrosis factor- α (TNF- α) blockade

TNF- α levels are elevated in children with KD,⁶⁸ and the TNF- α (-308) genetic polymorphism is associated with KD susceptibility, suggesting a role for TNF- α receptor blocking in the treatment of KD, especially for those patients/cases refractory to IVIG. The early administration of TNF- α receptor antagonists in KD may provide effective adjunctive therapy. Infliximab, which binds the proinflammatory cytokine TNF- α , has been evaluated in several studies and shown to have a significant effect in KD patients with IVIG resistance.^{69–71} Recently, etanercept, a more suitable TNF- α receptor blocker for children with refractory juvenile idiopathic arthritis,^{72,73} was reported to benefit the treatment of IVIG-resistant KD as an adjuvant therapy to initial IVIG.^{74,75} TNF- α receptor blocker may be administered after initial IVIG treatment failure or after a second dose of IVIG therapy.

4.6. Statins

Chronic vascular inflammation and endothelial dysfunction persists in KD patients with CAL, even long after the acute stage.^{76,77} There is currently no specific treatment for ongoing vascular inflammation and endothelial dysfunction. Low-dose aspirin can be prescribed until CAL normalizes, but it does not have an effect on inflammation or endothelial dysfunction. Lipid abnormalities in the acute phase of KD, with decreased triglycerides and high-density lipoprotein-cholesterol (HDL-C) levels have been reported in previous studies.^{78,79}

Statins, hydroxymethylglutaryl coenzyme A reductase inhibitors, have been shown to reduce cholesterol levels as well as improve surrogate markers of atherosclerosis and cardiovascular disease.⁸⁰ Huang et al⁸¹ reported that short-term (3 months) statin treatment (simvastatin, 10 mg/day as a single dose at bedtime) in KD patients complicated with CAL ($n = 11$) can significantly reduce total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) levels, and increase HDL-C level. Chronic vascular inflammation is also significantly improved, as well as endothelial dysfunction, with no adverse effects. However, long-term

and randomized control trials are needed before further conclusions can be made.

Recently, Blankier et al⁸² also reported that atorvastatin is able to inhibit critical steps (T cell activation and proliferation, production of the proinflammatory cytokine TNF- α , and up-regulation of matrix metalloproteinase-9 and an elastolytic protease) known to be important in the development of coronary aneurysms in an animal model of KD (murine model with injection of *Lactobacillus casei* cell wall extract), suggesting that statins may have therapeutic benefits in KD patients. Taken together, statins may be beneficial as an adjuvant therapy in KD patients with CAL. However, the association between dyslipidemia and atherosclerosis in KD patients is not certain.

4.7. Other treatments

Acute KD can lead to the development of large coronary artery aneurysms that may persist for years. Abciximab, a platelet glycoprotein IIb/IIIa receptor inhibitor, is associated with resolution of thrombi and vascular remodeling in adults with acute coronary syndromes. Williams et al⁸³ reported that KD patients who were treated with abciximab demonstrated greater regression in aneurysm diameter at early follow-up than patients who received standard therapy alone. McCandless et al⁸⁴ also reported that abciximab treatment might be associated with vascular remodeling in patients with aneurysms. Abciximab seems to benefit KD patients, especially those who developed aneurysms.

There are still no well-defined treatments for refractory KD. Suzuki et al⁸⁵ reported that cyclosporine A (CyA) treatment is considered safe and well-tolerated, and may serve as a promising option for patients with refractory KD. Hyperkalemia developed in 9/28 (32%) patients 3 to 7 days after commencing CyA treatment. Adverse effects such as arrhythmias should be monitored with CyA. Kuijpers et al⁸⁶ described a case of mortality, and a review of the literature showed that immunosuppressive medication such as CyA may not influence coronary inflammation and proliferation. Further trials are needed to clarify optimal dose, safety, and timing of CyA treatment.

Specific changes in inflammatory markers [such as white blood cell count, neutrophil count, CRP, IL-6, soluble IL-2 receptor (sIL-2R),⁸⁷ T helper type 17/regulatory T cell imbalance,⁸⁸ and IL-1 pathway⁸⁹] have been reported to disturb immunological functions and result in KD with IVIG resistance and CAL formation. This indicates the possible treatment role of plasma exchange (PE) for KD with IVIG resistance. Mori et al⁵⁹ studied 46 children who had not responded to the second IVIG treatment and subsequently received PE and compared them with 59 children that received a third dose of IVIG therapy. No complications occurred with PE therapy. CAL developed in eight of the 46 children (17.3%) who received PE and in 24 of the 59 (40.7%) who received a third course of IVIG ($p < 0.001$). PE is considered safe and effective in the prevention of CAL in KD that is refractory to IVIG therapy. PE could be performed at an early stage, as soon as fractional increases in inflammatory markers are found after first or second dosage of IVIG therapy.⁵⁹

5. Conclusions

The incidence of KD is increasing globally,^{6,8,90–95} especially in Asian countries.⁸ Incomplete presentation of clinical symptoms may complicate and delay the diagnosis of KD, or increase the rate of CAL. Supplementary criteria for diagnosing KD should be applied to every pediatric patient who experiences fever for more than 5 days (with two or three principal clinical features of KD) without a known infection source. Due to the rate of resistance to initial IVIG treatment, additional anti-inflammatory agents, a second dose of IVIG, IVMP, or TNF- α receptor blockers should be considered and administered as early as possible to diminish inflammation, endothelial dysfunction, and CAL formation. Because IVIG-resistant patients are at higher risk for CAL formation, it is important to identify those who may benefit from a more aggressive therapy. Early and appropriate treatment of KD may decrease the life-long sequelae of CAL in children.

Acknowledgments

This study was supported by funding (NSC 100-2314-B-182A-048-MY3) from the National Science Council of Taiwan.

References

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. *Pediatrics* 1974;**54**: 271–6.
2. Wang CL, Wu YT, Liu CA, Kuo HC, Yang KD. Kawasaki disease: infection, immunity and genetics. *Pediatr Infect Dis J* 2005;**24**: 998–1004.
3. Burns JC, Glode MP. Kawasaki syndrome. *Lancet* 2004;**364**: 533–44.
4. Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. *Acta Paediatr* 2010;**99**: 1578–83.
5. Park YW, Han JW, Park IS, et al. Kawasaki disease in Korea, 2003–2005. *Pediatr Infect Dis J* 2007;**26**: 821–3.
6. Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003–2006. *Pediatrics* 2009;**123**: e401–5.
7. Nakamura Y, Yashiro M, Uehara R, Oki I, Kayaba K, Yanagawa H. Increasing incidence of Kawasaki disease in Japan: nationwide survey. *Pediatr Int* 2008;**50**: 287–90.
8. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. *J Epidemiol* 2010;**20**: 302–7.
9. Liang CD, Kuo HC, Yang KD, Wang CL, Ko SF. Coronary artery fistula associated with Kawasaki disease. *Am Heart J* 2009;**157**: 584–8.
10. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on rheumatic fever, endocarditis and kawasaki disease, Council on cardiovascular disease in the young, American Heart Association. *Circulation* 2004;**110**: 2747–71.
11. Akagi T, Rose V, Benson LN, Newman A, Freedom RM. Outcome of coronary artery aneurysms after Kawasaki disease. *J Pediatr* 1992;**121**: 689–94.

12. Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. *Pediatr Clin North Am* 1995;**42**:1205–22.
13. Yu HR, Kuo HC, Sheen JM, et al. A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease. *Pediatr Allergy Immunol* 2009;**20**:699–707.
14. Wu MT, Hsieh KS, Lin CC, Yang CF, Pan HB. Images in cardiovascular medicine. Evaluation of coronary artery aneurysms in Kawasaki disease by multislice computed tomographic coronary angiography. *Circulation* 2004;**110**:e339.
15. Kuo HC, Yang KD, Juo SH, et al. ITPKC Single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. *PLoS One* 2011;**6**:e17370.
16. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. *N Engl J Med* 2007;**356**:663–75.
17. Shimizu C, Jain S, Davila S, et al. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. *Circ Cardiovasc Genet* 2011;**4**:16–25.
18. Kuo HC, Yu HR, Juo SH, et al. CASP3 gene single-nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. *J Hum Genet* 2011;**56**:161–5.
19. Kuo HC, Lin YJ, Juo SH, et al. Lack of association between ORAI1/CRACM1 gene polymorphisms and Kawasaki disease in the Taiwanese children. *J Clin Immunol* 2011;**31**:650–5.
20. Kuo HC, Wang CL, Liang CD, et al. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease. *J Microbiol Immunol Infect* 2007;**40**:395–400.
21. Kuo HC, Yang KD, Liang CD, et al. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. *Pediatr Allergy Immunol* 2007;**18**:354–9.
22. Kuo HC, Wang CL, Liang CD, et al. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease. *Pediatr Allergy Immunol* 2009;**20**:266–72.
23. Hsieh KS, Lai TJ, Hwang YT, et al. IL-10 promoter genetic polymorphisms and risk of Kawasaki disease in Taiwan. *Dis Markers* 2011;**30**:51–9.
24. Kuo HC, Wang CL, Wang L, Yu HR, Yang KD. Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease. *Pediatr Allergy Immunol* 2008;**19**:184–5.
25. Weng KP, Hsieh KS, Ho TY, et al. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. *Circ J* 2010;**74**:544–51.
26. Weng KP, Hsieh KS, Hwang YT, et al. IL-10 polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease. *Circ J* 2010;**74**:983–9.
27. Yu HR, Kuo HC, Huang EY, et al. Plasma clusterin levels in predicting the occurrence of coronary artery lesions in patients with Kawasaki disease. *Pediatr Cardiol* 2010;**31**:1151–6.
28. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. *Nat Genet* 2008;**40**:35–42.
29. Kuo HC, Chang WC. Genetic polymorphisms in Kawasaki disease. *Acta Pharmacol Sin* 2011;**32**:1193–8.
30. Kuo HC, Liang CD, Yu HR, et al. CTLA-4, position 49 A/G polymorphism associated with coronary artery lesions in Kawasaki disease. *J Clin Immunol* 2011;**31**:240–4.
31. Weng KP, Ho TY, Chiao YH, et al. Cytokine genetic polymorphisms and susceptibility to Kawasaki disease in Taiwanese children. *Circ J* 2010;**74**:2726–33.
32. Liu YC, Hou CP, Kuo CM, Liang CD, Kuo HC. Atypical Kawasaki disease: literature review and clinical nursing. *Hu Li Za Zhi* 2010;**57**:104–10 [In Chinese].
33. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. *J Cardiol* 2009;**53**:15–9.
34. Uehara R, Igarashi H, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guerin inoculation site. *Pediatr Infect Dis J* 2010;**29**:430–3.
35. Sonobe T, Kiyosawa N, Tsuchiya K, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. *Pediatr Int* 2007;**49**:421–6.
36. Chang FY, Hwang B, Chen SJ, Lee PC, Meng CC, Lu JH. Characteristics of Kawasaki disease in infants younger than six months of age. *Pediatr Infect Dis J* 2006;**25**:241–4.
37. Burns JC, Wiggins Jr JW, Toews WH, et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. *J Pediatr* 1986;**109**:759–63.
38. Heuclin T, Dubos F, Hue V, et al. Increased detection rate of Kawasaki disease using new diagnostic algorithm, including early use of echocardiography. *J Pediatr* 2009;**155**:695–9.
39. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. *Pediatrics* 2004;**114**:e689–93.
40. Kuo HC, Wang CL, Liang CD, et al. *Revisit high dose aspirin in acute stage of Kawasaki disease*. Taipei, Taiwan: 6th Asian Society for Pediatric Research; 2010.
41. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. *N Engl J Med* 1991;**324**:1633–9.
42. Wang CL, Wu YT, Liu CA, et al. Expression of CD40 ligand on CD4 + T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. *Pediatrics* 2003;**111**:e140–7.
43. Wang CL, Wu YT, Lee CJ, Liu HC, Huang LT, Yang KD. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease. *J Pediatr* 2002;**141**:560–5.
44. Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. *J Pediatr* 2004;**144**:496–9.
45. Fong NC, Hui YW, Li CK, Chiu MC. Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. *Pediatr Cardiol* 2004;**25**:31–4.
46. Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. *Circulation* 1993;**87**:1776–80.
47. Minich LL, Sleeper LA, Atz AM, et al. Delayed diagnosis of Kawasaki disease: what are the risk factors? *Pediatrics* 2007;**120**:e1434–40.
48. Anderson MS, Todd JK, Glode MP. Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. *Pediatrics* 2005;**115**:e428–33.
49. Marasini M, Pongiglione G, Gazzolo D, Campelli A, Ribaldone D, Caponnetto S. Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. *Am J Cardiol* 1991;**68**:796–7.
50. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. *J Pediatr* 2008;**153**:117–21.
51. Rigante D, Valentini P, Rizzo D, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. *Rheumatol Int* 2010;**30**:841–6.
52. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. *J Pediatr* 2011;**158**:831–5.

53. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. *J Pediatr* 2006;**149**:237–40.
54. Kuo HC, Wu CC, Yang TH, et al. Non-Langerhans cell histiocytosis in a child with Kawasaki disease. *BMJ Case Rep* 2009;**2009**:bcr11.2008.1227.
55. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. *J Pediatr* 1996;**128**:146–9.
56. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. *J Pediatr* 2011;**158**:644–9.
57. Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. *Scand J Rheumatol* 2005;**34**:136–9.
58. Pinna GS, Kafetzis DA, Tselkas OI, Skevaki CL. Kawasaki disease: an overview. *Curr Opin Infect Dis* 2008;**21**:263–70.
59. Mori M, Imagawa T, Katakura S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. *Mod Rheumatol* 2004;**14**:43–7.
60. Burns JC, Shimizu C, Shike H, et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. *Genes Immun* 2005;**6**:438–44.
61. Miura M, Kohno K, Ohki H, Yoshida S, Sugaya A, Satoh M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. *Eur J Pediatr* 2008;**167**:1119–23.
62. Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. *Arch Dis Child* 2008;**93**:142–6.
63. Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. *Arch Pediatr Adolesc Med* 2000;**154**:694–9.
64. Miura M, Ohki H, Yoshida S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. *Arch Dis Child* 2005;**90**:1096–7.
65. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. *Eur J Pediatr* 2009;**168**:181–5.
66. Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of refractory Kawasaki disease. *J Rheumatol* 2006;**33**:803–9.
67. Ogata S, Ogihara Y, Nomoto K, et al. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. *Pediatr Res* 2009;**66**:577–84.
68. Maury CP, Salo E, Pelkonen P. Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease. *J Lab Clin Med* 1989;**113**:651–4.
69. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. *J Pediatr* 2008;**153**:833–8.
70. Oishi T, Fujieda M, Shiraishi T, et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. *Circ J* 2008;**72**:850–2.
71. Zulian F, Zanon G, Martini G, Mescoli G, Milanese O. Efficacy of infliximab in long-lasting refractory Kawasaki disease. *Clin Exp Rheumatol* 2006;**24**:453.
72. Kuo HC, Yu HR, Wu CC, Chang LS, Yang KD. Etanercept treatment for children with refractory juvenile idiopathic arthritis. *J Microbiol Immunol Infect* 2011;**44**:52–6.
73. Guo MM, Yang KD, Yu HR, Kuo HC. Hypersensitive joint reaction after etanercept treatment in a patient with juvenile rheumatoid arthritis. *J Rheumatol* 2011;**38**:577–9.
74. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. *J Pediatr* 2010;**157**:960–6.
75. Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. *Am Heart J* 2011;**161**:494–9.
76. Senzaki H, Chen CH, Ishido H, et al. Arterial hemodynamics in patients after Kawasaki disease. *Circulation* 2005;**111**:2119–25.
77. Borzutzky A, Gutierrez M, Talesnik E, et al. High sensitivity C-reactive protein and endothelial function in Chilean patients with history of Kawasaki disease. *Clin Rheumatol* 2008;**27**:845–50.
78. Weng KP, Hsieh KS, Huang SH, Lin CC, Huang DC. Serum HDL level at acute stage of Kawasaki disease. *Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi* 1998;**39**:28–32.
79. Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. *Circulation* 1991;**84**:625–31.
80. Rodenburg J, Vissers MN, Wiegman A, Trip MD, Bakker HD, Kastelein JJ. Familial hypercholesterolemia in children. *Curr Opin Lipidol* 2004;**15**:405–11.
81. Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. *Circ J* 2008;**72**:1583–7.
82. Blankier S, McCrindle BW, Ito S, Yeung RS. The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. *Clin Exp Immunol* 2011;**164**:193–201.
83. Williams RV, Wilke VM, Tani LY, Minich LL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? *Pediatrics* 2002;**109**:e4.
84. McCandless RT, Minich LL, Tani LY, Williams RV. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease? *Am J Cardiol* 2010;**105**:1625–8.
85. Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. *Pediatr Infect Dis J* 2011.
86. Kuijpers TW, Biezeveld M, Achterhuis A, et al. Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. *Pediatrics* 2003;**112**:986–92.
87. Suzuki H, Suenaga T, Takeuchi T, Shibuta S, Yoshikawa N. Marker of T-cell activation is elevated in refractory Kawasaki disease. *Pediatr Int* 2010;**52**:785–9.
88. Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. *Clin Exp Immunol* 2010;**162**:131–7.
89. Fury W, Tremoulet AH, Watson VE, et al. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. *Hum Immunol* 2010;**71**:865–73.
90. Singh S, Aulakh R, Bhalla AK, et al. Is Kawasaki disease incidence rising in Chandigarh, North India? *Arch Dis Child* 2011;**96**:137–40.
91. Park YW, Han JW, Hong YM, et al. Epidemiological features of Kawasaki disease in Korea, 2006–2008. *Pediatr Int* 2011;**53**:36–9.
92. Piao JH, Jin LH, Lv J, Zhou Y, Jin CJ, Jin ZY. Epidemiological investigation of Kawasaki disease in Jilin province of China from 2000 to 2008. *Cardiol Young* 2010;**20**:426–32.
93. Lin YT, Manliot C, Ching JC, et al. Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. *Pediatr Int* 2010;**52**:699–706.
94. Ozdemir H, Ciftci E, Tapisiz A, et al. Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey. *J Trop Pediatr* 2010;**56**:260–2.
95. Guelmo E, Jones A, Ojiegbe J, Vanterpool H, Williams C, Mungrue K. Epidemiological trends of Kawasaki disease among paediatric patients admitted to the Wendy Fitzwilliam Paediatric Hospital, Trinidad, during 2004–2007. *Trans R Soc Trop Med Hyg* 2009;**103**:823–6.